SUBSCRIBE
SUBSCRIBE

Brandon May

Deals
Olema Oncology Prices IPO at $19 Per Share, Expects Gross Proceeds of $209 Million
In the IPO announcement, Olema Oncology notes it has granted the underwriters a 30-day option to buy up to 1,650,000 more common stock shares at the IPO price.
November 19, 2020
 · 
3 min read
 · 
Brandon May
Lenacapavir can be the first HIV capsid inhibitor.
Drug Development
Gilead’s Lenacapavir Shows Promise for Multidrug-Resistant HIV in Phase II/III Trial
Topline results from Gilead’s Phase II/III CAPELLA trial show that treatment with the company’s long-acting HIV-1 capsid inhibitor lenacapavir reduces HIV viral load better than placebo in heavily treated patients living with multidrug resistant HIV-1 infection.
November 18, 2020
 · 
3 min read
 · 
Brandon May
Pavel Kapysh/Shutterstock
Policy
FDA Lifts Hold on Cellectis’ Phase I MELANI-01 Trial After Key Safety Adjustments
The U.S. FDA has lifted a clinical hold on Cellectis’ Phase I MELANI-01 trial evaluating multiple myeloma candidate UCARTCS1 just months after working with the French biopharmaceutical company to adjust its trial protocol to enhance patient safety.
November 18, 2020
 · 
3 min read
 · 
Brandon May
photobyphm / Shutterstock
Drug Development
Bayer’s Finerenone Significantly Reduces CV Outcomes in CKD and T2D, According to New Data
Finerenone is an oral, non-steroidal selective mineralocorticoid receptor antagonist (MRA).
November 17, 2020
 · 
3 min read
 · 
Brandon May
Pavel Kapysh/Shutterstock
Drug Development
BrainStorm’s ALS Drug NurOwn Flops, But Signs of Efficacy Push Company to Continue R&D
A Phase III trial of NurOwn® (MSC-NTF cells), BrainStorm Cell Therapeutics’ investigational therapy for amyotrophic lateral sclerosis, did not find a statistically significant difference between the therapy and placebo for improving scores on a revised ALS functional rating scale.
November 17, 2020
 · 
3 min read
 · 
Brandon May
Drug Development
On the Heels of $46.7 Million Financing, Glympse Bio Announces Positive Data for NASH Sensors
Glympse Bio’s novel injectable mixture of synthetic sensors, which quantify protease activity and predict treatment response in non-alcoholic steatohepatitis (NASH), was demonstrated as safe and well-tolerated in healthy volunteers in a gene expression study of advanced fibrosis.
November 16, 2020
 · 
3 min read
 · 
Brandon May
Drug Development
Nkarta Treats First Patient in Phase I Trial for Relapsed/Refractory AMLS and MDS
Nkarta has treated its first patient in the first-in-human Phase I clinical trial of NKX101, an investigational immunotherapy designed to treat relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes.
November 13, 2020
 · 
3 min read
 · 
Brandon May
BioCapital
New Targeted Approach Could Prevent Toxicities Associated with Neurological Gene Therapies
Researchers from Penn Medicine have developed a new targeted approach that modifies viral vectors and inhibits toxicities in the sensory neurons of dorsal root ganglia that commonly occur following the use of gene therapy for neurological diseases.
November 12, 2020
 · 
2 min read
 · 
Brandon May
Business
New CDC Guidance Calls for Universal Mask Mandates to Protect Wearers, Others from COVID-19
After months of urging the public to wear masks and facial coverings to help stop infected people from spreading COVID-19, the Centers for Disease Control and Prevention now states in newly released guidance that masks also protected the mask wearer from being infected.
November 11, 2020
 · 
3 min read
 · 
Brandon May
Axovant Changes Name to Sio Gene Therapies, Adding to List of Biopharma Company Rebrands
Clinical-stage gene therapy company Axovant Gene Therapies is changing its name to Sio Gene Therapies, a move that will likely further distance the company from disappointing results of its Alzheimer’s candidate just three years ago.
November 10, 2020
 · 
3 min read
 · 
Brandon May
Drug Development
Study: Bristol Myers’ Deucravacitinib Improves Signs, Symptoms of Psoriatic Arthritis
A recent study shows that Bristol Myers Squibb’s oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib was associated with noticeable improvements in signs and symptoms of psoriatic arthritis compared with placebo.
November 9, 2020
 · 
3 min read
 · 
Brandon May
Drug Development
Inexpensive Nasal Spray Prevents COVID-19 Infection in Ferrets, Shows Promise for Human Trials
A multi-institutional research team has developed a nasal spray that effectively blocks absorption of the SARS-CoV-2 virus in ferrets with direct contact to infected animals.
November 6, 2020
 · 
3 min read
 · 
Brandon May
Potential MS Therapy Shows Promising Efficacy, Avoids Immune Suppression
Researchers from the Thomas Jefferson University have designed an antigen-specific therapy for the autoimmune disease multiple sclerosis (MS) using oligodendrocyte-derived extracellular vesicles.
November 5, 2020
 · 
3 min read
 · 
Brandon May
Anna in Sweden/Shutterstock
Pharm Country
Oxford-AstraZeneca’s Phase III COVID-19 Vaccine Data Could be Available by December
The Oxford and AstraZeneca co-developed COVID-19 vaccine could be one of the first vaccines submitted for regulatory approval, alongside Pfizer and BioNTech’s vaccine candidate BNT162b2.
November 4, 2020
 · 
3 min read
 · 
Brandon May
Lupus drug candidate BIIB059 showing promising res
Drug Development
Study: Biogen’s Lupus Drug Candidate BIIB059 Reduces Disease Activity Better Than Placebo
Additional findings from Biogen’s Phase II LILAC study, announced today, show the company’s lupus drug candidate BIIB059 is superior to placebo for reducing joint disease activity in patients with systemic lupus erythematosus.
November 3, 2020
 · 
3 min read
 · 
Brandon May
Load More